Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2021
BioLineRx completes $34.5 million public offering
BioLineRx completed an underwritten public offering after the end of 2020, raising gross proceeds of $34.5 million.
2020
BioLineRx reports first-quarter 2020 financial results
BioLineRx reported financial results for the quarter ended March 31, 2020, including a net loss of $6.6 million.
2020
BioLineRx receives USPTO patent notice of allowance
BioLineRx announced that the United States Patent and Trademark Office issued a Notice of Allowance for a patent application covering motixafortide in combination with any PD-1 inhibitor for treatment of any type of cancer.